Novo Nordisk A/S ADR(NVO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low46.66
Day High47.74
Open:47.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
FILE PHOTO: A general view shows Apotex pharmaceutical company as Humber River Hospital's mobile vaccine clinic vaccinate employees as part of the coronavirus disease (COVID-19) vaccination campaign, in Toronto, Ontario, Canada April 13, 2021. REUTERS/Carlos Osorio/File Photo
the globe and mail

Apotex emerges as only supplier of generic Ozempic in Canada for now

Issues at a manufacturing plant in India have sidelined two competitors
Motley Fool
Why Eli Lilly Topped the Market Today
Zacks Investment Research
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE)
Motley Fool
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem
Motley Fool
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound
Tipranks
Bank of America Securities Sticks to Its Hold Rating for Novo Nordisk (0QIU)
Tipranks
Deutsche Bank Remains a Hold on Novo Nordisk (0QIU)
Tipranks
Novo Nordisk (0QIU) Gets a Hold from Goldman Sachs
Tipranks
Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)
Motley Fool
Why Is Everyone Talking About Novo Nordisk?
Tipranks
Bernstein Reaffirms Their Sell Rating on Novo Nordisk (0QIU)
Zacks Investment Research
NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
Tipranks
UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)
Tipranks
Novo Nordisk Lifts 2026 Guidance as Wegovy Pill Drives Q2 Obesity Growth
Tipranks
Novo Nordisk (0QIU) Receives a Hold from Jefferies
Tipranks
Novo Nordisk Lifts 2026 Outlook After Strong Q2 Adjusted Results
Tipranks
Novo Nordisk Probes Thyroid Cancer Risk in Real‑World GLP‑1 Users
MarketBeat
The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic
MarketBeat.com
Tipranks
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Profile

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.